Novo Nordisk and Regeneron Pharmaceuticals represent distinct pharmaceutical investment opportunities. Novo Nordisk specialises in metabolic disorders, particularly diabetes and obesity treatments, serving patients in roughly 170 countries with a workforce of about 68,800. In fiscal 2025, Novo Nordisk generated nearly $47.7 billion in revenue, up 6.4% year-over-year, with net income of approximately $15.8 billion. The company's net margin stood at 33.1%, whilst its debt-to-equity ratio was 0.7x. Free cash flow reached nearly $4.5 billion. Regeneron focuses on treatments for eye diseases, cancer, and inflammatory conditions using proprietary technologies. The company maintains strategic partnerships with Sanofi and Bayer. In July 2026, Regeneron expanded its cancer therapy pipeline through collaboration with Telix Pharmaceuticals. Notably, two distributors accounted for roughly 77% of Regeneron's gross product revenue in 2025, creating customer concentration risk.

Supply Chain Digital's Transformation Project of the Year. September 14, 2026 Following on from the Global Supply Chain Awards, Supply Chain Digital take a look at the organisation recognised for the Transformation Project of the Year Award The Global Supply Chain Awards 2026 recognised companies who are going above and beyond, demonstrating excellence in a time of complexity. Leaders from around the world gathered on the 8 September, to see who won across the Global Supply Chain Awards, co-located with the Global Procurement Awards and the Global Sustainability Awards. Regeneron Pharmaceuticals gained recognition for its 'Speed to Science' project, earning the gold medal for the Transformation Project of the Year Award. Transformation Project of the Year. Supply chains have undergone significant changes in recent years, driven by ongoing volatility and the emergence of technology. The Transformation Project of the Year award acted as an opportunity to celebrate the organisations which have delivered successful transformation projects. It looked at those which have shown to improve efficiency, agility and performance through redesign, digitalisation or innovation. The nominees were: * Creating A Stronger, Smarter Global Supply Chain - East West Manufacturing * ATCO's Momentous, Really-Big-Deal Procurement Transformation - ProcureAbility - Jabil * Flow State: Turning Supply Fragility into Predictable Flow - Seqwater (Silver) * Transforming Healthcare Access: Building Integrated Digital Healthcare Ecosystem - Unitel LLC (Bronze) Regeneron Pharmaceuticals won the first place award with its project, Speed to Science: Transforming the Lab Supplies Category, Regeneron Pharmaceuticals. Regeneron in the lead. Every day, people are searching for answers to their illnesses, facing uncertainties about their health, their diagnosis and their treatments. Regeneron Pharmaceuticals aims to end this uncertainty, helping speed up the process of treatment without sacrificing quality. At Regeneron, teams of scientists, researchers and more are looking to deepen their understandings in order to advance research and unlock new innovations in healthcare. This project focused on rebuilding the company's lab supplies programme across three global sites in order to get the right products that allowed scientists to focus on their discoveries. Through this project, Regeneron achieved 85% adoption in year one, saving more than 750 administrative hours. This is a demonstration of the work Regeneron's team have been putting in in order to create a wider impact - by getting the right technology and the most effective products, teams have seen greater efficiency across one of the most critical supply chains. Winner insights. Upon receipt of this award, Supply Chain Digital spoke to Deborah Waterhouse, Associate Director at Regeneron. How does it feel to win this award? It feels great. Supply Chain Digital has worked hard as a team, not just who are here tonight, but also the team that Supply Chain Digital support. It's its stakeholders and its procurement leads and everybody else that supports the team. Could you tell me about the project and why you won this award? It was a lot of hard work. Supply Chain Digital has done a lot over the last 18 months of really focusing on what Supply Chain Digital needed to change within its supply chain and ensuring that Supply Chain Digital could move forward with transforming through sustainability solutions, through a value that Supply Chain Digital can deliver to the organisation. So delivering in so many opportunities and value beyond savings. How can supply chain leaders adapt to current world events? There's so much that Supply Chain Digital need to focus on. I think AI is going to play a big role in that as well, about how Supply Chain Digital use data and analytics to really support its organisations in the future. So it's very exciting to see how Supply Chain Digital can also adapt to that and really consider what is really, truly important going forwards. Finally, what does the future look like for your project? There's still a lot of work to be done. It never ends. So transformation means transformation. It requires a lot of change, people being on board for that and looking at what the next step is in its innovation and how Supply Chain Digital perform going forwards. Company Portals

Regeneron Pharmaceuticals' EYLEA franchise generated approximately $5.97 billion in US sales during 2024, according to a new market analysis report covering major pharmaceutical markets through 2034. The ophthalmology treatment addresses serious retinal diseases including neovascular age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Standard-dose EYLEA contributed approximately $4.77 billion in US sales during 2024. EYLEA HD, the 8mg formulation approved in 2023, generated approximately $1.2 billion in US sales during 2024. The higher-dose version supports longer treatment intervals for eligible patients, potentially reducing injection frequency compared with standard anti-VEGF dosing schedules. The report, added to ResearchAndMarkets.com's catalogue, covers seven major pharmaceutical markets including the United States, Germany, France, Italy, Spain, the United Kingdom and Japan, with historical analysis from 2020 and forecasts through 2034.